Middleton, MA – According to filings with the U.S. Securities and Exchange Commission, Forwardvue Pharma is raising $4,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Alan Franklin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Forwardvue Pharma

Motivated to improve the treatment burden of patients with retinal diseases. Novel vegf-independent drug delivery platform. Our lead molecule is a novel long acting ORAI1 blocker that acts both upstream and downstream of VEGF inhibition for durable administration up to 12 months to treat retinal neovascular disease.

To learn more about Forwardvue Pharma, visit http://forwardvuepharma.com/

Contact:
Alan Franklin, Chief Executive Officer
251-776-4455
alan@forwardvuepharma.com
https://www.linkedin.com/in/alan-franklin-4451881a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved